Ocrelizumab in Patients With Early-stage RRMS—Results from the Phase IIIb ENSEMBLE Trial and the Matched Real-world NTD MS Registry Cohort (P9-6.005)

Ocrelizumab in Patients With Early-stage RRMS—Results from the Phase IIIb ENSEMBLE Trial and the Matched Real-world NTD MS Registry Cohort (P9-6.005)

Abstract only

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Neurology 2024-04, Vol.102 (17_supplement_1)
Hauptverfasser: Hartung, Hans-Peter, Holmoy, Trygve, Wuerfel, Jens, Heer, Yanic, Braune, Stefan, Bergmann, Arnfin, Zuercher, Mel, Guye, Sabrina, Kuenzel, Thomas, Moore, Suzanne, Vollmer, Timothy
Format: Artikel
Sprache:eng
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page
container_issue 17_supplement_1
container_start_page
container_title Neurology
container_volume 102
creator Hartung, Hans-Peter
Holmoy, Trygve
Wuerfel, Jens
Heer, Yanic
Braune, Stefan
Bergmann, Arnfin
Zuercher, Mel
Guye, Sabrina
Kuenzel, Thomas
Moore, Suzanne
Vollmer, Timothy
description Abstract only
doi_str_mv 10.1212/WNL.0000000000205641
format Article
fullrecord <record><control><sourceid>crossref</sourceid><recordid>TN_cdi_crossref_primary_10_1212_WNL_0000000000205641</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>10_1212_WNL_0000000000205641</sourcerecordid><originalsourceid>FETCH-crossref_primary_10_1212_WNL_00000000002056413</originalsourceid><addsrcrecordid>eNqdkLtOwzAUhi0EEuHyBgxnhMHFTpo0XSlBRGpClUQqW-QmTmPkJMh2VYWJh0Di_XgSDEIMjJzll_7LcD6ELiiZUJe61-t0OSG_5xI_mNID5FDfDXDguY-HyLF2iL1wFh6jE62fCLHhbO6g94dKcSledh3bgOhhxYzgvdGwFqaFiCk5Ym3YlkOWJfnH61vG9U7avFFDB6blsGqZ5hDH8QaiNI-Sm2UEhRJMAuvr70bCTNXyGjLOJN4PStaQFreQ5NbZCm3UCIuhHZSBy9UcB_YV_-oMHTVMan7-o6doehcVi3tcqUFrxZvyWYmOqbGkpPyCUFoI5V8I3j9nn4QGZBs</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Ocrelizumab in Patients With Early-stage RRMS—Results from the Phase IIIb ENSEMBLE Trial and the Matched Real-world NTD MS Registry Cohort (P9-6.005)</title><source>Alma/SFX Local Collection</source><source>Journals@Ovid Complete</source><creator>Hartung, Hans-Peter ; Holmoy, Trygve ; Wuerfel, Jens ; Heer, Yanic ; Braune, Stefan ; Bergmann, Arnfin ; Zuercher, Mel ; Guye, Sabrina ; Kuenzel, Thomas ; Moore, Suzanne ; Vollmer, Timothy</creator><creatorcontrib>Hartung, Hans-Peter ; Holmoy, Trygve ; Wuerfel, Jens ; Heer, Yanic ; Braune, Stefan ; Bergmann, Arnfin ; Zuercher, Mel ; Guye, Sabrina ; Kuenzel, Thomas ; Moore, Suzanne ; Vollmer, Timothy</creatorcontrib><description>Abstract only</description><identifier>ISSN: 0028-3878</identifier><identifier>EISSN: 1526-632X</identifier><identifier>DOI: 10.1212/WNL.0000000000205641</identifier><language>eng</language><ispartof>Neurology, 2024-04, Vol.102 (17_supplement_1)</ispartof><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27901,27902</link.rule.ids></links><search><creatorcontrib>Hartung, Hans-Peter</creatorcontrib><creatorcontrib>Holmoy, Trygve</creatorcontrib><creatorcontrib>Wuerfel, Jens</creatorcontrib><creatorcontrib>Heer, Yanic</creatorcontrib><creatorcontrib>Braune, Stefan</creatorcontrib><creatorcontrib>Bergmann, Arnfin</creatorcontrib><creatorcontrib>Zuercher, Mel</creatorcontrib><creatorcontrib>Guye, Sabrina</creatorcontrib><creatorcontrib>Kuenzel, Thomas</creatorcontrib><creatorcontrib>Moore, Suzanne</creatorcontrib><creatorcontrib>Vollmer, Timothy</creatorcontrib><title>Ocrelizumab in Patients With Early-stage RRMS—Results from the Phase IIIb ENSEMBLE Trial and the Matched Real-world NTD MS Registry Cohort (P9-6.005)</title><title>Neurology</title><description>Abstract only</description><issn>0028-3878</issn><issn>1526-632X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><recordid>eNqdkLtOwzAUhi0EEuHyBgxnhMHFTpo0XSlBRGpClUQqW-QmTmPkJMh2VYWJh0Di_XgSDEIMjJzll_7LcD6ELiiZUJe61-t0OSG_5xI_mNID5FDfDXDguY-HyLF2iL1wFh6jE62fCLHhbO6g94dKcSledh3bgOhhxYzgvdGwFqaFiCk5Ym3YlkOWJfnH61vG9U7avFFDB6blsGqZ5hDH8QaiNI-Sm2UEhRJMAuvr70bCTNXyGjLOJN4PStaQFreQ5NbZCm3UCIuhHZSBy9UcB_YV_-oMHTVMan7-o6doehcVi3tcqUFrxZvyWYmOqbGkpPyCUFoI5V8I3j9nn4QGZBs</recordid><startdate>20240409</startdate><enddate>20240409</enddate><creator>Hartung, Hans-Peter</creator><creator>Holmoy, Trygve</creator><creator>Wuerfel, Jens</creator><creator>Heer, Yanic</creator><creator>Braune, Stefan</creator><creator>Bergmann, Arnfin</creator><creator>Zuercher, Mel</creator><creator>Guye, Sabrina</creator><creator>Kuenzel, Thomas</creator><creator>Moore, Suzanne</creator><creator>Vollmer, Timothy</creator><scope>AAYXX</scope><scope>CITATION</scope></search><sort><creationdate>20240409</creationdate><title>Ocrelizumab in Patients With Early-stage RRMS—Results from the Phase IIIb ENSEMBLE Trial and the Matched Real-world NTD MS Registry Cohort (P9-6.005)</title><author>Hartung, Hans-Peter ; Holmoy, Trygve ; Wuerfel, Jens ; Heer, Yanic ; Braune, Stefan ; Bergmann, Arnfin ; Zuercher, Mel ; Guye, Sabrina ; Kuenzel, Thomas ; Moore, Suzanne ; Vollmer, Timothy</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-crossref_primary_10_1212_WNL_00000000002056413</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Hartung, Hans-Peter</creatorcontrib><creatorcontrib>Holmoy, Trygve</creatorcontrib><creatorcontrib>Wuerfel, Jens</creatorcontrib><creatorcontrib>Heer, Yanic</creatorcontrib><creatorcontrib>Braune, Stefan</creatorcontrib><creatorcontrib>Bergmann, Arnfin</creatorcontrib><creatorcontrib>Zuercher, Mel</creatorcontrib><creatorcontrib>Guye, Sabrina</creatorcontrib><creatorcontrib>Kuenzel, Thomas</creatorcontrib><creatorcontrib>Moore, Suzanne</creatorcontrib><creatorcontrib>Vollmer, Timothy</creatorcontrib><collection>CrossRef</collection><jtitle>Neurology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Hartung, Hans-Peter</au><au>Holmoy, Trygve</au><au>Wuerfel, Jens</au><au>Heer, Yanic</au><au>Braune, Stefan</au><au>Bergmann, Arnfin</au><au>Zuercher, Mel</au><au>Guye, Sabrina</au><au>Kuenzel, Thomas</au><au>Moore, Suzanne</au><au>Vollmer, Timothy</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Ocrelizumab in Patients With Early-stage RRMS—Results from the Phase IIIb ENSEMBLE Trial and the Matched Real-world NTD MS Registry Cohort (P9-6.005)</atitle><jtitle>Neurology</jtitle><date>2024-04-09</date><risdate>2024</risdate><volume>102</volume><issue>17_supplement_1</issue><issn>0028-3878</issn><eissn>1526-632X</eissn><abstract>Abstract only</abstract><doi>10.1212/WNL.0000000000205641</doi></addata></record>
fulltext fulltext
identifier ISSN: 0028-3878
ispartof Neurology, 2024-04, Vol.102 (17_supplement_1)
issn 0028-3878
1526-632X
language eng
recordid cdi_crossref_primary_10_1212_WNL_0000000000205641
source Alma/SFX Local Collection; Journals@Ovid Complete
title Ocrelizumab in Patients With Early-stage RRMS—Results from the Phase IIIb ENSEMBLE Trial and the Matched Real-world NTD MS Registry Cohort (P9-6.005)
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-14T23%3A06%3A02IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-crossref&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Ocrelizumab%20in%20Patients%20With%20Early-stage%20RRMS%E2%80%94Results%20from%20the%20Phase%20IIIb%20ENSEMBLE%20Trial%20and%20the%20Matched%20Real-world%20NTD%20MS%20Registry%20Cohort%20(P9-6.005)&rft.jtitle=Neurology&rft.au=Hartung,%20Hans-Peter&rft.date=2024-04-09&rft.volume=102&rft.issue=17_supplement_1&rft.issn=0028-3878&rft.eissn=1526-632X&rft_id=info:doi/10.1212/WNL.0000000000205641&rft_dat=%3Ccrossref%3E10_1212_WNL_0000000000205641%3C/crossref%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true